ReviewInternational journal of molecular sciences2023
Radiogenomics in Renal Cancer Management-Current Evidence and Future Prospects.
Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A 23-year bibliometric analysis of the development of global research on hereditary renal carcinoma.Frontiers in oncology · 2024Pooled it
- Urinary MicroRNAs as Biomarkers of Urological Cancers: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- A radiogenomics biomarker based on tumor angiogenesis for non-invasive prognosis of clear cell renal cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Artificial intelligence in urological malignancy diagnosis and prognosis: current status and future prospects.The Canadian journal of urology · 2026Review
- Emerging Role of ctDNA Fragmentomics and Epigenetic Signatures in the Early Detection, Minimal Residual Disease Assessment, and Precision Monitoring of Renal Cell Carcinoma.Journal of cellular and molecular medicine · 2026Review
- CT-based radiogenomic prediction of ICAM1 and RAET1E as biomarkers of NK cytotoxicity in clear cell renal cell carcinoma.Frontiers in immunology · 2026Article
- From Radiomics to Radiogenomics: Decoding Renal Cell Carcinoma Biology for Precision Medicine-a narrative review.Insights into imaging · 2025Review
- CT radiomics for predicting postoperative disease specific survival in clear cell renal cell carcinoma: a multi-center study.Quantitative imaging in medicine and surgery · 2025Article
- State of the art review of AI in renal imaging.Abdominal radiology (New York) · 2025Review
- Machine learning-assisted radiogenomic analysis for miR-15a expression prediction in renal cell carcinoma.BMC cancer · 2025Article
- Computed tomography-based radiomics modeling to predict patient overall survival in cervical cancer with intensity-modulated radiotherapy combined with concurrent chemotherapy.The Journal of international medical research · 2025Observational
- Intratumoral and peritumoral radiomics using multi-phase contrast-enhanced CT for diagnosis of renal oncocytoma and chromophobe renal cell carcinoma: a multicenter retrospective study.Frontiers in oncology · 2025Article
- Deep Learning of radiology-genomics integration for computational oncology: A mini review.Computational and structural biotechnology journal · 2024Review
- Radiogenomics Pilot Study: Association Between Radiomics and Single Nucleotide Polymorphism-Based Microarray Copy Number Variation in Diagnosing Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.International journal of molecular sciences · 2024Article
- Empowering health care consumers & understanding patients' perspectives on AI integration in oncology and surgery: A perspective.Health science reports · 2024Article
- Exosome-related lncRNA score: A value-based individual treatment strategy for predicting the response to immunotherapy in clear cell renal cell carcinoma.Cancer medicine · 2024Article
- The efficacy of subsequent therapy after failure of anti-PD-1 antibody in metastatic renal cell carcinoma.Translational cancer research · 2024Article
- Human pan-cancer analysis of the predictive biomarker for the CDKN3.European journal of medical research · 2024Article
- Gross Hematuria Does not Affect the Selection of Nephrectomy Types for Clinical Stage 1 Clear Cell Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study.Annals of surgical oncology · 2024Article
- Radiogenomics and Texture Analysis to Detect von Hippel-Lindau (VHL) Mutation in Clear Cell Renal Cell Carcinoma.Current issues in molecular biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cancer management is challenging from diagnosis to treatment and follow-up. In cases of small renal masses and cystic lesions the differential diagnosis of benign or malignant tissues has potential pitfalls when imaging or even renal biopsy is applied. The recent artificial intelligence, imaging techniques, and genomics advancements have the ability to help clinicians set the stratification risk, treatment selection, follow-up strategy, and prognosis of the disease. The combination of radiomics features and genomics data has achieved good results but is currently limited by the retrospective design and the small number of patients included in clinical trials. The road ahead for radiogenomics is open to new, well-designed prospective studies, with large cohorts of patients required to validate previously obtained results and enter clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.